Highly sensitive single-molecule counting technology for cytokeratin 18 detection in non-alcoholic fatty liver disease using novel antibodies
Rattachement africain : cn, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Non-alcoholic fatty liver disease (NAFLD) affects approximately 25 % of the global population, presenting a significant threat to human health and imposing a substantial economic burden on society. Cytokeratin 18 (CK18) has emerged as a promising non-invasive biomarker for early detection of NAFLD. However, current diagnostic methods face challenges in accurately identifying NAFLD in its early stages. To address this issue, our study aimed to generate new CK18 antibodies and utilize a highly sensitive single-molecule immunodetection system customized for NAFLD. We embarked on a process involving the production of novel CK18 monoclonal antibodies, which were subsequently engineered into recombinant forms. In comparison to commercial antibodies, our antibodies exhibited superior affinity. Grounded in the SMCxPRO platform, our assay underwent rigorous assessment, adhering to well-defined biomarker assay criteria. The assay demonstrated specificity to CK18 and achieved a lower limit of quantification of 1 pg/ml. Importantly, elevated serum CK18 levels were observed among NAFLD patients compared to healthy individuals. The single-molecule detection system, utilizing our novel antibodies, holds significant promise for the early-stage diagnosis, dynamic disease monitoring, and prognostic evaluation of NAFLD patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Highly sensitive single-molecule counting technology for cytokeratin 18 detection in non-alcoholic fatty liver disease using novel antibodies
- Date Crossref
- 01/03/2024
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Capital Medical University Beijing Institute of Hepatology pays non établi dans la noticeUniversité ou école supérieure
-
Beijing YouAn Hospital pays non établi dans la noticeÉtablissement de santé
-
Shadyside Hospital pays non établi dans la noticeÉtablissement de santé
-
Beijing Ditan Hospital pays non établi dans la noticeÉtablissement de santé
-
Shady Side Academy pays non établi dans la noticeInstitution
Beijing Institute of Hepatology — Capital Medical University, Beijing YouAn Hospital et Shadyside Hospital, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.